Trials / Recruiting
RecruitingNCT05254574
Sustained Acoustic Medicine for Osteoarthritis Pain
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- ZetrOZ, Inc. · Industry
- Sex
- All
- Age
- 35 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare Sustained Acoustic Medicine treatment to topical pain relief gel for the symptomatic management of osteoarthritis. The study will measure pain and function scores for patients undergoing treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Sustained Acoustic Device with 2.5% Diclofenac Patch | Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm@ with 2.5% Diclofenac patches. |
| DRUG | 2.5% Diclofenac Patches | Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch. |
Timeline
- Start date
- 2022-02-14
- Primary completion
- 2026-05-01
- Completion
- 2026-05-31
- First posted
- 2022-02-24
- Last updated
- 2025-02-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05254574. Inclusion in this directory is not an endorsement.